Trending...
- Men's Health Network Highlights Major 2025 Achievements & Launches New Donation Platform For Greater Impact
- Australian Aboriginal Cultural Immersions and First Nations Workshops
- T-TECH Partners with Japan USA Precision Tools for 2026 US Market Development of the New T-TECH 5-Axis QUICK MILL™
Dementia Specialist, Dr. Jeffrey Gelblum, Expands the Infusion Center in his Jupiter Neurology Office.
JUPITER, Fla. - PennZone -- To accommodate the exploding need for neurology services in Palm Beach, Martin, and St. Lucie counties, Jupiter Neurologist, Dr. Jeff Gelblum, proudly announces the expansion of his in-office infusion center located at 601 University Boulevard, Suite 102, in Jupiter, Florida.
Dr. Gelblum observes that an explosion of newly approved IV therapies for the treatment of Alzheimer's, MS, myasthenia gravis, and migraine warrant his center's increased capacity for IV treatment.
"Our Jupiter Infusion Center had been running at full capacity, and with the approval of even more disease-modifying treatments for severe neurologic conditions, we are now poised to meet the growing needs of our tri-county clientele," states Dr. Gelblum.
The infusion center accepts most insurances and eagerly welcomes referrals from all physicians and specialists in the community, including rheumatologists and other neurologists.
More on The PennZone
He concludes, "Our state-of-the-art neurology practice provides this area with top-notch clinical, diagnostic, and infusion care. As our community grows, we are dedicated to fulfilling the growing expectations of our patients and colleagues."
About Jeffrey Gelblum, MD, FAAN
Dr. Jeffrey Gelblum is a board-certified neurologist with offices in Aventura and Jupiter, Florida. He has successfully treated thousands of patients over 25 years, from South Florida and worldwide. He is considered a global thought leader in the neurologic treatment of dementia, seizure disorders, Parkinson's, Diabetic and Peripheral Nerve Disorder, Covid Long-Hauler, trauma, chronic pain, and more. He has hosted educational symposia in the U.S. and overseas.
Dr. Gelblum maintains numerous research FDA-sponsored affiliations, providing patients immediate access to promising new treatment protocols. He is active in multiple community outreach programs to educate the public regarding the care and treatment of neurologic disorders.
Learn more about Dr. Gelblum at https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Dr. Gelblum observes that an explosion of newly approved IV therapies for the treatment of Alzheimer's, MS, myasthenia gravis, and migraine warrant his center's increased capacity for IV treatment.
"Our Jupiter Infusion Center had been running at full capacity, and with the approval of even more disease-modifying treatments for severe neurologic conditions, we are now poised to meet the growing needs of our tri-county clientele," states Dr. Gelblum.
The infusion center accepts most insurances and eagerly welcomes referrals from all physicians and specialists in the community, including rheumatologists and other neurologists.
More on The PennZone
- 6 Holiday Looks That Scream "Old Money" But Cost Less Than Your Christmas Tree
- Tickeron Launches Next-Gen AI Corridor Bots: Consistent Exits for Stocks and ETFs
- From Cheer to Courtroom: The Hidden Legal Risks in Your Holiday Eggnog
- Controversial Vegan Turns Rapper Launches First Song, "Psychopathic Tendencies."
- Inside the Fight for Affordable Housing: Avery Headley Joins Terran Lamp for a Candid Bronx Leadership Conversation
He concludes, "Our state-of-the-art neurology practice provides this area with top-notch clinical, diagnostic, and infusion care. As our community grows, we are dedicated to fulfilling the growing expectations of our patients and colleagues."
About Jeffrey Gelblum, MD, FAAN
Dr. Jeffrey Gelblum is a board-certified neurologist with offices in Aventura and Jupiter, Florida. He has successfully treated thousands of patients over 25 years, from South Florida and worldwide. He is considered a global thought leader in the neurologic treatment of dementia, seizure disorders, Parkinson's, Diabetic and Peripheral Nerve Disorder, Covid Long-Hauler, trauma, chronic pain, and more. He has hosted educational symposia in the U.S. and overseas.
Dr. Gelblum maintains numerous research FDA-sponsored affiliations, providing patients immediate access to promising new treatment protocols. He is active in multiple community outreach programs to educate the public regarding the care and treatment of neurologic disorders.
Learn more about Dr. Gelblum at https://www.fcneurology.net/business-directory/788/jeffrey-gelblum-md/
Source: First Choice Neurology
Filed Under: Health
0 Comments
Latest on The PennZone
- New YouTube Channel Pair Launches to Bring Entertainment Nostalgia Back to Life
- BRAG Hosts Holiday Benefit — Awards 10 Student Scholarships & Honors Timberland with the Corporate Impact Award
- FittingPros Launches Industry's First Data-Driven Golf Club Fitting Directory
- African American Genealogy Group Launches 2025 Raffle Fundraiser to Support Legacy Research
- Take Control of Your Color Matching with Boston Industrial Solutions' Newly Expanded Natron® UVPX Series Ink Colors
- "Dr. Vincent Michael Malfitano Expands Monterey–Sicily Cultural Diplomacy With Major International Media Engagement"
- Kaufman Development Breaks Ground on Detroit Micro Data Center, Expanding Its National AI Platform
- Cummings Graduate Institute for Behavioral Health Studies Celebrates New DBH Graduates
- $80M+ Backlog as Florida Statewide Contract, Federal Wins, and Strategic Alliance Fuel Next Phase of AI-Driven Cybersecurity Growth: Cycurion $CYCU
- High-Conviction CNS Disruptor Aiming to Transform Suicidal Depression, Ketamine Therapeutics, and TMS - Reaching Millions by 2030
- Top10Christmas.co.uk Releases the UK Christmas Toy Trends 2025 Report
- Talagat Business Academy Announces Joint Certificate Program With The University of Chicago Booth School of Business
- LocaXion and Asseco CEIT Announce First-to-Market RTLS-Driven Digital Twin Platform for Healthcare, Manufacturing, and Logistics
- Slotozilla Launches New Report on How AI Is Reshaping Careers and Society
- OKAVA Pharmaceuticals Announces First Cat Dosed in MEOW-1 Study of OKV-119, the World's First Clinical-Stage GLP-1 Weight-Loss Therapy for Pets
- Explosive Growth in U.S. Cryptocurrency Cloud Mining Sets The Stage for New Platform Launch with Daily Rewards in a Transparent Revenue-Share Model
- Qtex Cierra Ronda de $7 Millones para Estandarizar la Banca Transfronteriza en los Mercados Emergentes de Latinoamérica
- Ring in the Season with Free Holiday Jazz from The Jazz Sanctuary
- America's Most Festive Garages Wanted for Garage.com's 2025 Holiday Contest
- FDA Accepts ANDA for KETAFREE™ as Analyst Sets $34 Price Target for NRx Pharmaceuticals: (N A S D A Q : NRXP) NRx is Poised for a massive Breakthrough
